This morning we watched Acadia Healthcare rise 14.2% to a price of $74.09 per share. The Mid-Cap Medical Specialities company is now trading -16.52% below its average target price of $88.75. Analysts have set target prices ranging from $70.0 to $105.0 per share for Acadia Healthcare, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 3.9%, and a short ratio of 4.7. Since 2.97% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 104.3% of Acadia Healthcare's shares being owned by this investor type.
Institutions Invested in Acadia Healthcare
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 10% | 8,856,436 | $656,173,310 |
| 2024-03-31 | T. Rowe Price Investment Management, Inc. | 9% | 8,524,274 | $631,563,429 |
| 2024-03-31 | Blackrock Inc. | 9% | 8,230,812 | $609,820,830 |
| 2024-03-31 | Wellington Management Group, LLP | 9% | 7,916,966 | $586,567,981 |
| 2024-03-31 | FMR, LLC | 6% | 5,386,915 | $399,116,512 |
| 2024-03-31 | Invesco Ltd. | 4% | 3,281,289 | $243,110,689 |
| 2024-03-31 | Dimensional Fund Advisors LP | 3% | 3,170,529 | $234,904,481 |
| 2024-03-31 | William Blair Investment Management, LLC | 3% | 2,911,394 | $215,705,170 |
| 2024-03-31 | JP Morgan Chase & Company | 3% | 2,848,093 | $211,015,199 |
| 2024-03-31 | State Street Corporation | 3% | 2,731,797 | $202,398,829 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Acadia Healthcare.
